SCHEMBL5760903

SCHEMBL5760903

C/C(=C/C(=O)c1ccc(C(F)(F)F)cc1)NC(Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccsc12)C(=O)O

nearest known ligand 0.68

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 20/20 0.68
PPARG P37231 19/20 0.68
PPARD Q03181 5/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7250828 0.94 PPARA (0.66) PPARAPPARGPPARD
SCHEMBL5763593 0.93 PPARG (0.69) PPARAPPARGPPARD
SCHEMBL5761917 0.89 PPARG (0.67) PPARAPPARGPPARD
SCHEMBL5763014 0.87 PPARG (0.67) PPARAPPARGPPARD
SCHEMBL6600238 0.84 PPARG (0.66) PPARAPPARGPPARD
SCHEMBL5762484 0.83 PPARG (0.64) PPARAPPARGPPARD
SCHEMBL6604525 0.83 PPARG (0.85) PPARAPPARGPPARD
SCHEMBL6604535 0.83 PPARG (0.85) PPARAPPARGPPARD
SCHEMBL27573438 0.83 PPARG (0.85) PPARAPPARGPPARD
SCHEMBL6604544 0.83 PPARG (0.85) PPARAPPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1392295-B1 CARBOXYLIC ACID SUBSTITUTED OXAZOLE DERIVATIVES FOR USE AS PPAR-ALPHA AND -GAMMA ACTIVATORS IN THE TREATMENT OF DIABETES HOFFMANN LA ROCHE (CH) 2006-05-31 EP disclosed
US-6642389-B2 For therapy of diabetes HOFFMANN-LA ROCHE INC. 2003-11-04 US disclosed
US-20030055265-A1 Oxazole derivatives HOFFMANN-LA ROCHE INC. 2003-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055265-A1 Oxazole derivatives PPARD, PPARA, PPARG PPARA 2/4885PPARG 3/4885PPARD 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.